24 Flashcards
- Patients with some type of MDS are at increased risk of developing
A. acute lymphoblastic leukemia
B. AML
C. chronic lymphocytic leukemia
D. chronic myelogenous leukemia
B. AML
- Which of the following agents has not been supported by scientific research as being associated with the development of secondary
MDSs?
A. Alkylating agents
B. Organic solvents
C. Insecticides
D. Both B and C
D. Both B and C
- An increased incidence of MDSs is seen in
A. males younger than 55 years of age
B. females younger than 55 years of age
C. males older than 55 years of age
D. females older than 55 years of age
C. males older than 55 years of age
- The most frequently involved chromosomes in adults with MDSs are
A. 1, 5, and 7
B. 3, 5, and 8
C. 5, 7, and 8
D. 8, 12, and 13
C. 5, 7, and 8
- The most frequent chromosomal abnormalities in children with MDSs include all of the following except
A. trisomy 8
B. monosomy 7
C. deletion of long arm of chromosome 20
D. all of the above
D. all of the above
- The incidence of chromosomal abnormality in adults with MDSs is
A. 5% to 15%
B. 15% to 25%
C. 25% to 60%
D. 40% to 90%
D. 40% to 90%
- The karyotype associated with a high probability of transforming to
AML is
A. monosomy 5
B. monosomy 7
C. trisomy 11
D. both A and B
D. both A and B
- Patients with MDSs commonly suffer from ______ initially.
A. a rash
B. anemia
C. visual disturbances
D. vertigo
B. anemia
An appropriate description of refractory anemia (RA) is
A. anemia, no blast
B. anemia, less than 1% blasts
C. cytopenia, less than 5% blasts, no Auer rods
B. anemia, less than 1% blasts
An appropriate description of refractory anemia with ring sideroblats (RARS) is
A. anemia, no blasts
B. anemia, less than 1% blasts
C. cytopenia, less than 5% blasts, no Auer rods
A. anemia, no blasts
An appropriate description of refractory anemia with excess blasts, type 1 RAEB
A. anemia, no blasts
B. anemia, less than 1% blasts
C. cytopenia, less than 5% blasts, no Auer rods
C. cytopenia, less than 5% blasts, no Auer rods
In young patients, the therapy of choice for MDSs involves
A. vitamins
B. allogeneic bone marrow transplantation
C. cytotoxic drugs
D. colony-stimulating growth factors
B. allogeneic bone marrow transplantation